US Stock Market Closed

Dashboard

Puma Biotechnology, Inc. (PBYI)

bolt HIT FAIR VALUE

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

B

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

CEO

Alan H. Auerbach

Employees

269

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

Los Angeles

Exchange

NASDAQ

Summary Stats

Market Cap

194M

Revenue

218M

Net Income

9.73M

EPS

$0.22

Price-to-Earnings

18.98

Price-to-Book

8.78

Debt-to-Equity

7.97

News

Analyst Ratings

Price targets projected by 7 analysts

High

$15.00

Average

$9.14

Low

$6.00

Ratings calculated by 8 analysts

Buy

1

Hold

3

Sell

4

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.10

Actual

$0.05 +200.0%

Consensus

-0.05

Report Date

Year Ago

-0.99

Year Ago Change %

Up 105%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites